Research programme: anti-fibroproliferative small molecule therapeutics - Celgene/PharmAkea

Drug Profile

Research programme: anti-fibroproliferative small molecule therapeutics - Celgene/PharmAkea

Alternative Names: Cancer and fibrotic disease oral therapies - Celgene/PharmAkea; Fibroproliferative disease therapies - Celgene/PharmAkea

Latest Information Update: 23 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PharmAkea Therapeutics
  • Developer Celgene Corporation; PharmAkea Therapeutics
  • Class Small molecules
  • Mechanism of Action Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; Connective tissue disorders

Most Recent Events

  • 18 Nov 2016 PharmAkea and Celgene Corporation extend the term of their agreement for fibrotic diseases
  • 04 Oct 2013 Early research in Cancer and Connective tissue disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top